Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU

IF 6.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2025-05-02 DOI:10.1111/apt.70172

María José Casanova, Cristina Rubín de Célix, Sabino Riestra, Alfredo J. Lucendo, José Manuel Benítez, Mercè Navarro-Llavat, Jesús Barrio, Víctor J. Morales-Alvarado, Montserrat Rivero, David Busquets, Eduardo Leo-Carnerero, Oscar Nantes-Castillejo, Pablo Navarro, Manuel Van Domselaar, Ana Gutiérrez-Casbas, Inmaculada Alonso-Abreu, Manuel Barreiro-de Acosta, Luis Fernández-Salazar, Marisa Iborra, María Dolores Martín-Arranz, Natalia García-Morales, Jordi Guardiola, Abdel Bouhmidi-Assakali, María Esteve, Carmen Muñoz-Villafranca, Iago Rodríguez-Lago, Daniel Ceballos, Iván Guerra, Miriam Mañosa, Ignacio Marín-Jiménez, Isabel Vera-Mendoza, Ana Garre, María Chaparro, Javier P. Gisbert

引用次数: 0

Abstract

The EXIT trial found no difference in sustained remission at 12 months between inflammatory bowel disease (IBD) patients in remission who withdrew anti-TNF therapy [withdrawal arm (WA)] and those who maintained treatment [maintenance arm (MA)].

Abstract Image

查看原文本刊更多论文

炎症性肠病患者在缓解期停止抗肿瘤坏死因子治疗后的长期结果：GETECCU的长期研究

EXIT试验发现，处于缓解期的炎症性肠病（IBD）患者退出抗tnf治疗[停药组（WA）]和维持治疗[维持组（MA）]的患者在12个月的持续缓解方面没有差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.